Pancreatic Cancer with Cachexia
Conditions
Interventions
None listed
Sponsors
Japanese Foundation for Cancer Research
The University of Tokyo Hospital Showa Medical University Northern Yokohama Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Diagnosed with pancreatic cancer 2.Initiating anamorelin treatment for cancer cachexia 3.Age 18 years or older at registration 4.Written informed consent obtained
Exclusion criteria
Exclusion criteria: 1.Unable to independently remove anamorelin tablets dispensed with CubixxDT Japanese version 2.Difficulty participating due to clinically significant psychiatric or neurological symptoms 3.Severe cognitive impairment 4.Native language is not Japanese 5.Unable to use ePRO
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Longitudinal changes in medication adherence rate to anamorelin assessed by CubixxDT (Japanese version) from baseline to 24 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| Beliefs about medicines and medication adherence trends assessed by BMQ; Longitudinal changes in health related QOL scores assessed by FAACT ACS and EQ 5D 5L from baseline to 24 weeks; Association between medication adherence rates and health related QOL scores; Association between adherence rates measured by CubixxDT and BMQ scores; Exploratory analysis of reasons for non adherence | — |
Countries
Japan
Contacts
Public ContactKazuo Kobayashi
Cancer Institute Hospital of Japanese Foundation for Cancer Research Department of Pharmacy
Outcome results
None listed